Leukocare Biotechnology

Leukocare Biotechnology is a Munich-based service provider specializing in data-science-driven formulation development for biologics and ATMPs. Founded in 2009, its core offering combines a proprietary AI/ML platform (ExPreSo) for excipient screening with predictive stability analytics to significantly shorten traditional formulation development cycles. The company operates as a service-based CRO, with a proven track record evidenced by over 350 stable drug-product recipes delivered for clients including BioNTech, Xellia, and Formycon. Its value proposition centers on de-risking development and accelerating time-to-IND/BLA for its biopharma partners.

AI/ML-driven SMART Formulation platform featuring ExPreSo (Excipient Prediction Software) for rational excipient screening and predictive stability analytics using kinetic modeling and machine learning to forecast degradation and shelf-life.

Leukocare competes with traditional formulation service arms of large CROs (e.g., Lonza, Catalent) and specialized biopharma CMOs. Its primary differentiation is its proprietary, AI-driven platform (ExPreSo). Emerging competition includes other AI/ML startups focusing on drug discovery and development optimization, which may expand into formulation.